Article Text

Download PDFPDF

Determining the microbiological cause of a chest infection
  1. Julia E Clark
  1. Correspondence to Dr Julia E Clark, Paediatric Infectious Diseases, Infection Management and Prevention Service, Royal Children's Hospital, Level 1, South Tower, RCH, Herston, Brisbane, QLD 4029, Australia; Julia.clark{at}health.qld.gov.au

Abstract

Over recent years non-culture techniques such as specific viral and bacterial nucleic acid amplification, serology and antigen detection have considerably developed and been applied within research studies to clinical samples, significantly increasing pathogen detection in pneumonia. There are promising signs of improved diagnostic yields for pneumococcal pneumonia when using molecular techniques to detect pneumococcal gene sequences in blood or by combining serum biomarkers with rapid pneumococcal urinary antigen testing. Pathogens have traditionally been difficult to detect in pneumonia and treatment is usually successful with empiric antibiotics. However, directed antibiotic treatment has significant benefits in terms of antibiotic stewardship and these new technologies make this goal a possibility, though not yet a reality.

  • Infectious Diseases
  • Microbiology
  • Respiratory
  • Virology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Why identify the microbiological cause of a chest infection?

Community-acquired pneumonia (CAP) in children remains an important cause of mortality and morbidity,1 accounting for a significant proportion of hospital admissions worldwide. Despite this, for an individual child presenting with pneumonia the microbiological cause is rarely determined.2 ,3 The reasons for this appear to be twofold. First, children are usually treated with antibiotics and they recover, thus rendering the necessity of a microbiological diagnosis unnecessary for treatment.2 ,3 Second, the limited ability to obtain lower respiratory tract secretions or sputum from children given their poor tussive force and inability to expectorate makes it difficult to obtain adequate specimens for bacterial identification. However, identifying pathogens both at the individual and population level is extremely important. Within populations, monitoring changes in aetiology and resistance patterns over time, and after the introduction of immunisation, allows assessment of the impact of immunisation programmes, appropriate empiric antibiotic selections, decreases inappropriate antibiotic use and enhances antimicrobial stewardship. At an individual level, a microbiological diagnosis may also aid clinicians in targeting narrow spectrum antibiotic treatment or even to withdraw antibiotics, as well as provide short-term and long-term prognoses in terms of empyema, bronchiectasis or the likelihood of effects on lung function.4 Although determining the cause for individual patients is challenging, management guidelines2 ,3 recognise the importance of attempting to do so in children hospitalised with severe CAP.

How to identify the cause?

Alternatives for detecting the pathogen: clinical, radiological, biochemical features

Bacterial and viral pneumonia cannot be differentiated reliably on clinical or radiological grounds,2 ,3 ,5 although the presence of pleural effusions suggests pneumococcal infection.6 The clinical features of CAP (fever, tachypnoea, breathlessness or difficulty in breathing, cough, wheeze, chest pain) vary and tend not to be specific for bacterial or viral infections. Mycoplasma pneumonia is the possible exception, where chest pain is frequently noted.7 Aetiology is difficult to assign radiologically as mild bacterial infections often produce less marked changes on the chest radiograph and conversely, some severe viral infections produce lobar changes.5 ,8

The use of biomarkers, either on their own or within clinical prediction rules, has been explored. In children with fever, C-reactive protein (CRP) and procalcitonin (PCT) performed better than interferons or erythrocyte sedimentation rate at ruling-in rather than ruling-out bacterial infections.9 High levels of PCT (>1.5 ng/mL) and CRP (>100 mg/L) have been strongly associated with pneumococcal CAP, with a sensitivity of 94.4% for PCT and 91.9% for CRP.10 Although PCT is a promising biomarker in adults with pneumonia, its diagnostic threshold in childhood pneumonia is less defined and its usefulness and safety in guiding management have not been established. If levels of PCT and CRP are very high, then bacterial pneumonia is likely; however, positive and negative predictive values are not yet discriminating enough to rely on for treatment decisions.9 ,11 In the future, increasingly sophisticated clinical prediction rules incorporating biomarkers and clinical features may be usefully incorporated as a clinical decision-making tool.

Pathogen detection: what tests can be done?

Bacterial culture

Microscopy, bacterial culture and antimicrobial sensitivity testing of suitable bodily fluids have been the mainstay for bacterial diagnosis and require routine laboratory facilities and skills. However, there are limitations to its specificity, with some inaccuracies in distinguishing between Streptococcus pneumoniae and other viridans streptococci using routine phenotyping methods (specificity range, 85%–95%).12 ,13 Culture is also influenced by inadequate specimen sampling such as poor sputum quality, insufficient blood culture volume, delayed processing of specimens and prior antibiotic use. It is also relatively slow and insensitive.

New bacterial identification techniques including matrix-assisted laser desorption ionisation time-of-flight mass spectrometry are increasingly routinely available for identification of cultured bacteria from solid or liquid media (saving at least 1 day on traditional methods requiring subculture, phenotyping and biochemical tests) hence with advantages in speed and volume, though as yet no great improvement is seen in discriminatory capacity between the S pneumoniae and viridans groups.12 Rapid advances in this technology continue and their performance in specificity is expected to improve.12

Antibody detection

Antibody detection is utilised in both viral and bacterial infections, by detecting rising titres of immunoglobulin G (IgG) antibody between acute and convalescent sera or by detecting IgM acutely in primary infection. Different assays are available, with differences in sensitivity and specificity or type of antibody detected. Some assays, such as enzyme immunoassays and radioimmunoassays, detect either IgM or IgG and others, such as complement fixation tests and haemagglutination inhibition, detect only total antibody. Interpretation of results is aided by understanding which tests the local clinical laboratory performs. IgM assays can lack specificity with cross reactivity and persistent IgM and IgG testing is limited to retrospective diagnoses, as detection of a significant rise in IgG antibody titres requires two samples at least 1–2 weeks apart.

Serology has conventionally been used for respiratory viruses and certain bacteria including Mycoplasma pneumoniae, Chlamydia spp, Streptococcus pyogenes, Legionella spp, Francisella tularensis and Coxiella burnetii. Mycoplasma IgM, IgA and IgG have historically been the mainstay of diagnosis for this infection.

Antibody detection has also been explored for other bacterial diagnoses including pneumococcus, Haemophilus and Moraxella, as have circulating immune complexes containing both pneumococcal microbial antigens and antibodies. Most are not well validated and not routinely available in clinical diagnostic laboratories. However, recent developments in pneumococcal antibody detection from evaluations of conjugate pneumococcal vaccines have resulted in a WHO standardised serotype-specific anti-pneumococcal IgG ELISA.14 This was recently evaluated and validated in children with pneumonia; the IgG ELISA correctly identifying infecting serotype in 82% and an IgA ELISA in 59% of the cases.14

Although bacterial serological tests are not affected by prior antibiotic exposure and do not require isolation of bacteria, pneumococcal antibody detection has the potential to detect antibodies against colonising pneumococci, which may be confounded by pneumococcal immunisation and also provides only retrospective diagnosis. They are, therefore, primarily useful in epidemiological surveillance studies and have limited value in acute clinical diagnoses.

Antigen detection

Viral antigens can be detected either in cells collected from the site of infection by immunohistochemical staining or in secretions and blood by solid phase immunoassays. Labelling viral antigens with immunofluorescent (IF) monoclonal antibody was widely adopted in the 1980s and allowed rapid diagnosis of viral respiratory viruses, commonly respiratory syncytial virus (RSV), influenza A and B, parainfluenza and adenovirus. IF sensitivity is, however, dependent on specimen quality and despite its relatively low cost has generally been superseded by the more sensitive detection of specific viral nucleic acids by PCR in high income countries.

Pneumococcal antigen detection is readily available and widely used in adults. This test uses a rapid, sensitive immunochromatographic test (ICT) to detect the C polysaccharide cell wall antigen common to all strains of S pneumoniae and is commercially available for use on urine samples (Binax NOW).13 Pneumococcal capsular polysaccharide detection either by ELISA or multiplex IAs are also being developed and are sensitive and specific and can identify serotypes.12 Refinements to this test have increased its sensitivity and specificity, though are not yet commercially available.12

Nucleic acid amplification; for example PCR

Rapid advances in PCR techniques and reliability mean that real time (RT) PCR has become commercially viable, allowing PCR to become routinely available for the detection of respiratory viruses. Multiplex PCR approaches to viral detection on respiratory specimens are common and bacterial multiplex PCRs are also developing.15 As costs decrease and multiplex testing is more often available, the feasibility of performing multiple specific PCR tests on a single sample will improve.

For S pneumoniae, the pneumolysin gene (ply), autolysin gene (lytA), pneumococcal surface adhesin A gene (psaA), wzg/cpsA and the Spn9802 gene fragment have all been used as PCR targets and several PCR methods for the identification of S pneumoniae have been developed. Currently a dual target PCR (lyt A and ply) gives the best sensitivity and specificity.12 ,16 Additionally RT PCR allows rapid serotyping, with 21 primer/probe sets targeting regions of the CpsA gene specific for 21 serotypes.17

Pan-bacterial PCRs targeting the common bacterial 16S ribosomal RNA and allowing nonspecific bacterial identification are an attractive concept, but appear less sensitive than specific PCRs.18

Practical application of microbiological tests

How should samples be taken?

Correct samples are needed to make a definitive microbiological diagnosis. Easily accessible samples include blood, urine, nose and throat swabs and nasopharyngeal aspirates (NPAs). In children, it is often difficult to obtain adequate sputum specimens, but when possible they are also useful. Additionally, the utility of induced sputum is currently being explored.19 Samples requiring invasive procedures including bronchoalveolar lavage and lung aspiration are infrequently done and may require sedation or a general anaesthetic in children.

It is important to recognise that the method and site of respiratory sampling can impact on yield. For example, the overall sensitivity of viral detection with NPA samples is higher than that obtained with nasal swab (NS) samples. NS is an inadequate sample if IF is used for viral detection, but if PCR methods are used, diagnostic yields are comparable except for RSV.20 Adenovirus may be more frequently detected on NPA samples than nasal washes, whereas the reverse may be true for coronavirus.21

Which tests can be performed on respiratory secretions?

A century ago, sputum and lung aspirates were obtained routinely and microbiological methods were refined, resulting in an extremely high identification of causative pathogens.22 A failure of diagnostic testing is not just isolated to children. In his review, Bartlett displays sequential studies showing that the yield of pneumococcal identification in adults dropped from 81% in the 1930s to 12% in 2003 and 7.6% in 2009. This does not reflect a dramatic decline in pneumococcal infection but rather the lack of diagnostic microbiology performed as well as longer time to present and lower use of presampling antibiotics in historical cases. A major component of diagnosis was previously lung aspiration. Lung aspirates in children increase the diagnostic yield, successfully identifying pathogens in approximately 60% of children, and are still performed in selected populations.23 However, given lung aspirates have a small risk of serious adverse events and most children with pneumonia recover uneventfully, these are generally performed clinically only where the diagnostic benefits outweigh the risks.

Though nasopharyngeal secretions, nose swabs and throat swabs are frequently and easily obtained in children and multiplexed respiratory viral PCRs are routinely available, allowing rapid viral identification, bacterial PCRs remain difficult to interpret. Their diagnostic discrimination is limited by their ability to determine infection from colonisation or prolonged shedding, especially for S pneumoniae in young children. This may also be true for Mycoplasma PCR on NPAs24 and, although not well explored, viral carriage and prolonged shedding are also a clinical possibility.25 As molecular diagnostics improve and become more sensitive this issue becomes more relevant.12 There is some promising evidence to suggest that quantitative pneumococcal PCRs may be able to differentiate infection from colonisation;26 ,27 however, at present bacterial PCRs when applied to upper airway secretions not clinically useful in CAP.

Which tests can be performed on blood samples?

Blood culture is influenced by prior antibiotics and requires a high bacterial load for successful culture. Most children are not bacteraemic even with bacterial pneumonia,2 ,28 ,29 although in a series of children hospitalised mostly with lobar pneumonia or effusions, 9% had positive blood cultures.16 When positive, cultures are usually S pneumoniae, but occassionally Staphylococcus aureus especially in complicated pneumonia.30

Except for M pneumoniae, serology in most cases is impractical, given the need for acute and convalescent samples seldom achieved. Group A streptococcal infection (GAS) is also usefully diagnosed by serology, and though important in terms of severity, this infection is frequently overlooked, despite often progressing to intensive care admission or empyema31 and being found in up to 10% of hospitalised CAP.28

Pneumococcal antibody and antigen testing on blood are not routinely available in most centres and remain useful mainly in the context of epidemiological research. Both have been usurped in the clinical arena with the advent of PCR.

There is accumulating evidence for the use and validity of pneumococcal RT PCR in children with pneumonia. The application of RT PCR on blood, targeting either the ply gene32 or lytA gene17 improves pneumococcal detection between 232 and 516 ,17 times. Reassuringly, RT PCR using lytA as the target gene, appears specific, and is not detected in healthy carriers.33 Quantitative RT PCR may be predictive of pneumonia severity as a few studies have demonstrated that a high bacteraemic DNA load was associated with increased mortality.34

Which tests can be performed on pleural fluid?

Pleural fluid is an excellent specimen for microbiological identification, although it requires an invasive procedure to obtain, and thus usually a general anaesthetic in children. Gram stain of pleural fluid has a good positive predictive value but is insensitive.12 Applying non-culture techniques to pleural fluid increases diagnostic yields significantly. Antigen detection using latex agglutination and ICTs as well as PCR have been described. Latex agglutination has been variously successful, with positive results between 25% and 90%.35 ,36 Binax NOW is sensitive (71%–96%) and specific (71%–100%),12 though performs less well than pleural fluid PCR does.36

Pneumococcal PCRs have been applied to pleural fluid in many studies, with up to 75% infections identified as pneumococcal.35 ,37 Pleural fluid pneumococcal serotyping by either PCR16 ,32 ,37 or multiplex IAs for capsular polysaccharides35 often identifies serotype 1 as predominant.

Multiplex RT PCRs have successfully detected S pneumoniae and S aureus (including methicillin-resistant), S pyogenes, Haemophilus influenzae (HI) and M pneumoniae in 84% of pleural fluid; significantly better than by culture.37 A 16S ribosomal DNA PCR has also improved bacterial detection, in one study identifying an additional 28% of pathogens, mostly pneumococcal but also GAS, S aureus and haemophilus influenzae (HI).36 However, when compared with species specific PCR, 16S PCR appears less sensitive.18

Which tests can be performed on urine?

Urine is easily obtainable and the Binax NOW S pneumoniae assay is recommended in diagnostic testing in adults.12 In children, there have been concerns that urinary antigen testing is confounded by pneumococcal carriage, vaccination and prolonged excretion of pneumococci.12 ,13 It may, however, be more specific for disease in symptomatic children and has recently been suggested that it may be a useful diagnostic adjunct in older children.10 ,38

What are the microbiological causes of a chest infection?

Aetiological studies have been attempted in many different countries and populations, all using different combinations of the identification techniques described above, with varying success and different proportions of bacteria and viruses identified. Recent studies using both molecular and serological diagnoses identify a cause in between 60% and 80%.2 ,28 ,29

Respiratory viruses are often detected, particularly in young children, either alone or as copathogens, but their true pathogenicity can be difficult to interpret as community controls are rarely included in pneumonia studies. RSV is consistently the most common pathogen detected,2 ,39 followed by rhinovirus, and in varying proportions depending on the population and season, human metapneumovirus and human bocavirus,39 then influenza and adenovirus.28

The relative contribution of bacteria has changed over the last 20 years with the introduction of first H influenzae type b (HiB), then pneumococcal conjugate vaccines (PCVs). Vaccine-probe studies in unvaccinated populations estimate that S pneumoniae and HiB respectively contribute up to 30% and 18% of radiologically confirmed pneumonia in young children.40 ,41 Since the introduction of PCV7 in the UK, hospitalised pneumonia reduced by 19% in those aged under 5 years, and 33.1% in those aged under 2 years.42 However, even in vaccinated populations, S pneumoniae remains the most frequent bacterial cause, with most pneumococcal serotypes detected not included in the conjugate vaccine.16 ,17 ,28 With the introduction of PCV and decrease in pneumococcal pneumonia, it is possible that the relative proportion of bacteria such as GAS and S aureus as well as M pneumoniae causing severe pneumonia will increase.

When should we investigate?

It is important to explore aetiology at a population level in order to monitor over time, assess the impact of immunisation programmes and monitor antibiotic resistance patterns. However, despite benefits of identifying a pathogen for an individual child, the uncertainty of microbiological findings and the difficulty of obtaining samples, as well as the expense of non-culture techniques, means that, in practice, for a child with pneumonia in the community setting, extensive microbiological tests are not yet useful. Some national guidelines advocate respiratory virus testing3 for both outpatients and hospitalised children; as a positive viral diagnosis without suggestion of bacterial coinfection could decrease inappropriate antimicrobial therapy. With worldwide concerns about antibiotic resistance and increasing awareness of the importance of antibiotic stewardship in children, this strategy will become increasingly examined. For children with severe pneumonia admitted to hospital for supportive care and antibiotics, securing a microbiological diagnosis (box 1) has benefits; positive tests for respiratory viruses may guide antiviral therapy in influenza, may decrease inappropriate antimicrobial therapy and guide prognosis, while rapid bacterial identification could direct appropriate narrow spectrum antibiotic therapy.

Box 1 Suggested initial investigations for hospitalised children with severe community-acquired pneumonia

  • Respiratory secretions (Sputum, nasopharyngeal aspirates, nasal swabs, throat swabs):

    • Respiratory viruses PCR and mycoplasma PCR if clinically indicated

  • Blood culture

  • Mycoplasma IgM, IgG

  • Blood pneumococcal real time (RT) PCR (if available and targeting ply and lyt A genes)

  • Pleural fluid:

    • Pneumococcal RT PCR

    • Or BinaxNOW

  • Urinary BinaxNOW (older children aged over 5 years)

References

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.